Showing results (41-50 of 292) with videos related to
Sort By:
Pageof 30
Clinical Pharmacology : Advances and Applications|October 31, 2017
Possible involvement of ROS generation in vorinostat pretreatment induced enhancement of the antibacterial activity of ciprofloxacinMajed M Masadeh, Karem H Alzoubi, Sayer I Al-Azzam, et al.Clinical Pharmacology : Advances and Applications|February 7, 2018
A review of the pharmacology and clinical efficacy of brivaracetamPavel Klein, Anyzeila Diaz, Teresa Gasalla, et al.Clinical Pharmacology : Advances and Applications|February 8, 2013
A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulationKoen van Rossem, Jenny A LoweClinical Pharmacology : Advances and Applications|March 2, 2013
Effect of statin therapy on vaspin levels in type 2 diabetic patientsSayer I Al-Azzam, Karem H Alzoubi, Jaafar Abu Abeeleh, et al.Clinical Pharmacology : Advances and Applications|May 3, 2013
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitorVijay V Upreti, Yan Song, Jessie Wang, et al.Clinical Pharmacology : Advances and Applications|December 4, 2012
Sedation in the intensive care settingChristopher G Hughes, Stuart McGrane, Pratik P PandharipandeClinical Pharmacology : Advances and Applications|October 10, 2013
Atazanavir-bilirubin interaction: a pharmacokinetic-pharmacodynamic modelRoberto Lozano, Nieves Domeque, Alberto-Fermin ApesteguiaClinical Pharmacology : Advances and Applications|October 10, 2014
Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogensTetsuya MatsumotoClinical Pharmacology : Advances and Applications|May 19, 2026
Recurrent/Refractory Multidrug- and Pre-Multidrug-Resistant Pseudomonas aeruginosa Infection Cases Maintained by Long-Term, Low-Dose Macrolide AdministrationMasafumi SekiClinical Pharmacology : Advances and Applications|November 2, 2016
LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectivesFarzaneh Atashrazm, Nicolas DzamkoPageof 30